Literature DB >> 19858537

Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein.

Alfonso Cristaudo1, Rudy Foddis, Alessandra Bonotti, Silvia Simonini, Agnese Vivaldi, Giovanni Guglielmi, Rossella Bruno, Debora Landi, Federica Gemignani, Stefano Landi.   

Abstract

BACKGROUND: Serum mesothelin, also known as soluble mesothelin-related protein (SMRP), reportedly shows increased levels in epithelial-type malignant pleural mesothelioma, but sometimes also arrives at high values in healthy asbestos-exposed subjects.
OBJECTIVES: This study aimed to investigate whether single nucleotide polymorphisms in the 3'untranslated region (3'UTR) of the mesothelin-encoded gene (MSLN) are associated with the SMRP levels measured in serum.
METHODS: The 3'UTR of the mesothelin gene was genotyped in 59 healthy asbestos-exposed subjects, selected on the basis of their SMRP levels. Direct sequencing did not show any new polymorphism, but enabled us to genotype two known SNPs (rs1057147, rs57272256). Differences in the mean values of SMRP in wild-type and variant heterozygote groups were calculated.
RESULTS: High levels of SMRP in healthy asbestos-exposed subjects were significantly associated with polymorphism rs1057147 (G<A). Regarding rs57272256, there was no statistically significant difference between wild-type and heterozygote groups. Our study suggests that rs1057147 polymorphism can affect mesothelin expression. Although these data need to be confirmed with a larger number of cases, this study warrants further research in order to better understand the relationship between mesothelin polymorphisms and SMRP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858537     DOI: 10.1136/oem.2009.049205

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  7 in total

1.  Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population.

Authors:  Min Yu; Yixiao Zhang; Zhaoqiang Jiang; Junqiang Chen; Lihong Liu; Jianlin Lou; Xing Zhang
Journal:  Environ Health Prev Med       Date:  2015-07-19       Impact factor: 3.674

Review 2.  Biomarkers in the prevention and follow-up of workers exposed to asbestos.

Authors:  Rudy Foddis; Alessandra Bonotti; Stefano Landi; Poupak Fallahi; Giovanni Guglielmi; Alfonso Cristaudo
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

3.  The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.

Authors:  Heather H Nelson; Lindsay M Almquist; Jessica L LaRocca; Silvia L Plaza; Geralyn M Lambert-Messerlian; David J Sugarbaker; Raphael Bueno; John J Godleski; Carmen J Marsit; Brock C Christensen; Karl T Kelsey
Journal:  Epigenetics       Date:  2011-08-01       Impact factor: 4.528

4.  Factors that impact susceptibility to fiber-induced health effects.

Authors:  Jennifer E Below; Nancy J Cox; Naomi K Fukagawa; Ari Hirvonen; Joseph R Testa
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

Review 5.  Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.

Authors:  Zehra Nur Töreyin; Manosij Ghosh; Özlem Göksel; Tuncay Göksel; Lode Godderis
Journal:  Int J Environ Res Public Health       Date:  2020-02-10       Impact factor: 3.390

6.  Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine.

Authors:  David Roulois; Sophie Deshayes; Marie-Noëlle Guilly; Joëlle S Nader; Charly Liddell; Myriam Robard; Philippe Hulin; Amal Ouacher; Vanessa Le Martelot; Jean-François Fonteneau; Marc Grégoire; Christophe Blanquart; Daniel L Pouliquen
Journal:  Oncotarget       Date:  2016-06-07

7.  Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.

Authors:  Katja Goricar; Viljem Kovac; Metoda Dodic-Fikfak; Vita Dolzan; Alenka Franko
Journal:  Radiol Oncol       Date:  2020-03-07       Impact factor: 2.991

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.